Yahoo Web Search

Search results

  1. Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment.

  2. Innovative products, therapies and services creating a future worth living for our patients. Chronic and acute kidney dialysis and therapeutic apheresis.

  3. Fresenius Medical Care Singapore has been providing dialysis products and life-saving therapies since 1997 with a simple yet powerful mission: To improve the quality of life for people living with chronic kidney disease.

  4. Treatment of anaemia. Vaccination. High quality care by our care tea. Regular nephrologist visits. Please talk to your doctor about the treatment options available and which best suits your needs. Email fmc.sg@fmc-asia.com to make an appointment today. More information.

  5. Fresenius Medical Care offers products and services along the entire dialysis value chain from a single source. We care for more than 332,000 patients in our global network of roughly 4,000 dialysis clinics.

  6. Fresenius Kidney Care is the dialysis care services division of Fresenius Medical Care, the world's leading provider of products and services for individuals living with renal disease. We provide treatments and care that fits with patients' needs, allowing them to lead more active and fulfilling lives. 344,687.

  7. Supporting medical and scientific education of healthcare professionals. Fresenius Medical Care Ventures was established to invest in start-ups and early-stage companies in the healthcare sector.

  8. Fresenius Medical Care provides healthcare professionals with products and solutions for patients renal failure and CKD. Learn more about our product line.

  9. The Fresenius Kidney Care PatientHub allows you to view lab results, track your supply order and plan ahead. Use your mobile app for info on the go.

  10. Europe's leading private healthcare provider. News. Brief News. Positive CHMP Opinion for FYB202, an Ustekinumab Biosimilar Candidate.

  1. People also search for